S-glycoside Patents (Class 514/24)
-
Publication number: 20090318371Abstract: The present invention relates to a topical preparation for treating acne in the form of a gel and cream comprising Retinoid (Tazarotene or Adapalene) Antibiotic (Clindamycin Phosphate) and/or Keratolytic (Benzoyl Peroxide in microsponges) as active ingredients and a carrier formulated with all or some of the following components: Polyoxyl 35 castor oil Propylene glycol Glycerine, Carbomer, Triethanolamine, EDTA, Emulsifying nonionic wax (Polawax) Ethanol Antioxidants and Preservatives. The present invention advantages regarding state of the art compositions are based on the fact that the present antiacne composition contains a Retinoid, and Antibiotic and/or a Keratolytic agent which allow the control of every kind of acne from mild to vulgar offering less adverse effects.Type: ApplicationFiled: July 25, 2007Publication date: December 24, 2009Inventor: Fernando Ahumada Ayala
-
Publication number: 20090305999Abstract: The object is to provide a novel application of D-allose (e.g., use for prevention of hypertension or hypercardia). Thus, disclosed is a composition for preventing the increase in blood pressure which comprises D-allose as an active ingredient; or a composition containing D-allose and/or a derivative thereof, preferably in an amount of 0.1 to 50% by weight. Preferably, the composition is in a form selected from the group consisting of a food additive, a food material, a beverage/food, a health beverage/food, a pharmaceutical and a feeding stuff which can be used for the prevention and treatment of a cardiovascular system disorder (e.g., hypertension, hypercardia). The increase in blood pressure may be caused by salt-sensitive hypertension. Also disclosed is use of D-allose for preventing the increase in blood pressure (excluding medical practices).Type: ApplicationFiled: August 31, 2006Publication date: December 10, 2009Applicants: NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY, FUSHIMI PHARMACEUTICAL CO., LTD.Inventors: Masaaki Tokuda, Shoji Kimura, Ken Izumori
-
Publication number: 20090306000Abstract: A method of generating synthetic metabolites of tanaproget derivatives thereof is provided. These compounds and methods of using these derivatives for detecting tanaproget metabolites in samples are provided.Type: ApplicationFiled: June 26, 2009Publication date: December 10, 2009Applicant: WyethInventors: Li Shen, Kelly Keating, Oliver McConnell, William DeMaio, Appavu Chandrasekaran
-
Patent number: 7622451Abstract: Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders.Type: GrantFiled: May 10, 2007Date of Patent: November 24, 2009Assignee: University of KansasInventors: Brian Blagg, Mary Lou Michaelis, Michelle McIntosh
-
Publication number: 20090275524Abstract: The present invention relates to novel hypocholesterolemic compounds of formula (I) useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels as well as to pharmaceutical compositions comprising said compounds alone or in combination with other active agentsType: ApplicationFiled: May 7, 2009Publication date: November 5, 2009Inventors: Erick Carreira, Helmut Hauser, Lisbet Kvaerno, Tobias Ritter, Moritz Werder
-
Patent number: 7608594Abstract: Novel analogues and derivatives of novobiocin are provided, including compounds having modifications to the amide side chain, coumarin ring, and sugar moieties. The compounds of the present invention are useful as heat shock protein 90 inhibitors, and may be used as anticancer and neuroprotective agents.Type: GrantFiled: November 3, 2005Date of Patent: October 27, 2009Assignee: University of KansasInventors: Brian S. Blagg, Len Neckers, Xiao Ming Yu
-
Publication number: 20090247477Abstract: Administration of the isothiocyanate protects against UV light-induced skin carcinogenesis. In particular, topical application or dietary administration of isothiocyanate sulforaphane after exposure to UV radiation provides effective protection against skin tumor formation. Sulforaphane analogs and glucosinolates also can be employed. Lotions useful for suppressing UV light-induced skin carcinogenesis also are provided.Type: ApplicationFiled: April 27, 2006Publication date: October 1, 2009Inventors: Paul Talalay, Albena T. Dinkova-Kostova
-
Publication number: 20090217924Abstract: There is disclosed a system comprising a fluid reservoir, a liquid solution within the reservoir, the solution comprising an antibiotic of the lincomycin family, a spray nozzle, a spray activator, and a tubular connection connecting the spray nozzle and the fluid reservoir.Type: ApplicationFiled: February 28, 2008Publication date: September 3, 2009Inventor: Gregory William Pearson
-
Publication number: 20090186834Abstract: Various azetidinone, pyrrolidine, imidazolidine, and oxazolidine derivatives are described, as are pharmaceutical compositions containing these compounds and methods of treatment of diseases using these compounds. Other embodiments are also described.Type: ApplicationFiled: March 24, 2006Publication date: July 23, 2009Applicant: MICROBIA, INC.Inventors: John Talley, Eduardo Martinez, Daniel Zimmer, Regina Lundrigan
-
Publication number: 20090176717Abstract: Compositions and methods are provided related to Pseudomonas bacteria. The compositions and methods may be used for diagnosis and therapy of medical conditions involving infection with Pseudomonas bacteria. Such infections include Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. A compound useful in the present methods may be used in combination with a therapeutic agent or may be linked to a therapeutic agent. Pseudomonas bacteria may be inhibited by blocking colonization, inhibiting virulence factors, arresting growth or killing the bacteria.Type: ApplicationFiled: May 30, 2007Publication date: July 9, 2009Applicant: GlycoMimetics, Inc.Inventor: John L. Magnani
-
Patent number: 7553819Abstract: Novel glycerol cyclic pyruvate derivates were prepared and demonstrated to inhibit the binding of an immobilized D-proline derivative to serum amyloid P component (SAP) have been prepared. As such, the compounds of the invention are useful for treating amyloidosis and diseases associated with amyloidosis, for example Alzheimer&supl;s disease and maturity onset diabetes mellitus.Type: GrantFiled: May 12, 2004Date of Patent: June 30, 2009Assignee: Theracarb Inc.Inventors: David Bundle, Pavel Kitov, Kenneth Kai-Sing Ng, Jason Gay Shuen Ho
-
Patent number: 7524510Abstract: Described herein are methods for the noninvasive immunization of a subject that involve alkyl glycosides. Also described herein are compositions, kits, and devices for the noninvasive immunization of a subject.Type: GrantFiled: February 23, 2006Date of Patent: April 28, 2009Assignee: The UAB Research FoundationInventors: John Jefferson Arnold, Chun-Ming Huang, Elias Meezan, Dennis J. Pillion, De-Chu C. Tang
-
Patent number: 7514411Abstract: This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure wherein R1, R2, R3, R4, R5, R6, R7, W, Y, and Z are defined herein; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 17, 2006Date of Patent: April 7, 2009Assignee: WyethInventors: Scott C. Mayer, Robert E. McDevitt, Paul J. Dollings
-
Patent number: 7501399Abstract: This invention provides compounds containing a 2-deoxy-2-amino-?-D-glucopyranose (glucosamine) glycosidically linked to an cyclic aminoalkyl (aglycon) group. The invention further provides methods for inducing an immune response using the compounds of the present invention in the presence or absence of an antigen. In addition, methods for treating disease with the compounds of the present invention with or without an antigen are also provided in this invention.Type: GrantFiled: September 11, 2006Date of Patent: March 10, 2009Assignee: Corixa CorporationInventors: David A. Johnson, Jory Baldridge, C. Gregory Sowell
-
Publication number: 20080312164Abstract: The present invention provides glucosinolate and isothiocyante compounds and related methods for synthesizing these compounds and analogs. In certain embodiments, these glucosinolate and isothiocyanate compounds are useful and chemopreventive and or chemotherapeutic agents.Type: ApplicationFiled: July 13, 2007Publication date: December 18, 2008Inventors: Scott R. Rajski, Jared Rae Mays
-
Patent number: 7442687Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described herein.Type: GrantFiled: August 2, 2005Date of Patent: October 28, 2008Assignee: The University of Virginia Patent FoundationInventors: Jayson M. Rieger, Joel M. Linden, Timothy L. Macdonald, Gail W. Sullivan, Lauren J. Murphree, Robert Alan Figler, Robert Douglas Thompson
-
Patent number: 7439232Abstract: There is provided a heteroaryl 5-thio-?-D-glucopyranoside compound of the following formula, which has an inhibitory effect on SGLT2 activity, or a pharmaceutically acceptable salt thereof or a hydrate thereof. There is also provided a pharmaceutical preparation, particularly a prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which comprises such a compound as an active ingredient.Type: GrantFiled: February 6, 2004Date of Patent: October 21, 2008Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Hiroyuki Kakinuma, Masakazu Sato, Hideaki Amada, Hajime Asanuma, Yuko Tsuchiya
-
Publication number: 20080161247Abstract: The present disclosure provides a composition for enhancing effect of an inhibitor in inhibiting NAD+/NADP+ or NADH/NADPH dependent enzymes. The inhibition of the NAD+/NADP+ or NADH/NADPH dependent enzymes such as Enoyl-ACP reductase (ENR) by the composition of the present disclosure serves as a target for treating malaria and other infectious diseases. The present disclosure provides composition comprising inhibitor and polyphenol, wherein the polyphenol was found to enhance the inhibitory activity of the inhibitor. The present disclosure provides method for treating an infectious disease comprising administering an effective amount of the composition of the present disclosure to patients in need thereof.Type: ApplicationFiled: December 19, 2007Publication date: July 3, 2008Inventors: Avadhesha Surolia, Shailendra K. Sharma, Namita Surolia, Prasanna Parasuraman, Gyanendra Kumar
-
Patent number: 7390785Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: GrantFiled: November 7, 2005Date of Patent: June 24, 2008Assignees: The University of Utah Research Foundation, Cognetix, Inc.Inventors: Craig Walker, Reshma Shetty, Baldomero M. Olivera, David Hooper, Richard Jacobsen, Doug Steel, Robert Jones
-
Publication number: 20080076723Abstract: The present invention provides a candidate compound that is suitable for use in methods of treating animals (preferably mammals) and in the preparation of a medicament, wherein the candidate compound down regulates Cathepsin K activity.Type: ApplicationFiled: September 27, 2006Publication date: March 27, 2008Applicant: Sylvan Pharmaceuticals Pty Ltd.Inventors: David Cullis-Hill, Robert Logan Hannon, Christopher Bond Little, Margaret Mary Smith
-
Patent number: 7323452Abstract: A method for accelerating the process of removing ethanol from the blood through the use of certain additives that accelerate the metabolic oxidation of ethanol, and others which in addition act as catalysts or “pseudo” enzymes for the oxidation. These additives include multivalent transition metal ions, as well as complexes thereof, and NAD+ which enhance the oxidation reaction. The method described can act as a sobriety inducer and/or as an effective palliative for the unpleasant effects of overuse of ethanol.Type: GrantFiled: December 20, 2004Date of Patent: January 29, 2008Assignee: Wardan, L.L.C.Inventors: Ward B. Bowen, Jr., Daniel S. Daniel
-
Publication number: 20080003262Abstract: A method for treating non-infectious inflammatory vulvovaginitis comprises administering to a vulvovaginal surface a pharmaceutical composition that comprises clindamycin in an amount of about 125 mg to about 400 mg per unit dose of the composition; wherein the composition is bioadhesive to the vulvovaginal surface, and upon application of the composition to the vulvovaginal surface the clindamycin is released over a period of about 3 hours to about 14 days. A related method comprises administering to a vulvovaginal surface a pharmaceutical composition comprising clindamycin or a pharmaceutically acceptable salt or ester thereof, wherein the composition has at least one non-lipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. A pharmaceutical composition comprises (a) clindamycin or a pharmaceutically acceptable salt or ester thereof in a clindamycin equivalent amount of about 2.Type: ApplicationFiled: June 28, 2007Publication date: January 3, 2008Applicant: DrugTech CorporationInventors: R. Saul Levinson, Robert C. Cuca, Jonathan Bortz
-
Patent number: 7256177Abstract: Novel lincomycin derivatives are disclosed. These lincomycin derivatives exhibit antibacterial activity. The compounds of the subject invention may exhibit potent activities against bacteria, including Gram positive organisms, and may be useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.Type: GrantFiled: November 17, 2004Date of Patent: August 14, 2007Assignee: Vicuron Pharmaceuticals, Inc.Inventors: Jason G. Lewis, Sampath K. Anandan, Hardwin O'Dowd, Mikhail F. Gordeev
-
Patent number: 7223737Abstract: The topical use of glycosides for the treatment of dry eye disorders is disclosed.Type: GrantFiled: August 10, 2005Date of Patent: May 29, 2007Assignee: Alcon, Inc.Inventors: Victor Ke, legal representative, Tai-Lee Ke, deceased
-
Patent number: 7199106Abstract: Novel lincomycin derivatives are disclosed. These lincomycin derivatives exhibit antibacterial activity. The compounds of the subject invention may exhibit potent activities against bacteria, including gram positive organisms, and may be useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.Type: GrantFiled: June 17, 2004Date of Patent: April 3, 2007Assignee: Vicuron Pharmaceuticals, Inc.Inventors: Jason G. Lewis, Sampath-Kumar Anandan, Hardwin O'Dowd, Mikhail F. Gordeev
-
Patent number: 7199105Abstract: Novel lincomycin derivatives are disclosed. These lincomycin derivatives exhibit antibacterial activity. As the compounds of the subject invention exhibit potent activities against bacteria, including gram positive organisms, they are useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.Type: GrantFiled: February 11, 2004Date of Patent: April 3, 2007Assignee: Vicuron Pharmaceuticals, Inc.Inventors: Jason G. Lewis, Dinesh V. Patel, Sampath Kumar Anandan, Mikhail F. Gordeev
-
Patent number: 7183261Abstract: Galactosylceramide analogues represented by the following formula (1) or (2). (wherein X and Y each represent S or O, R1 and R2 each represent an alkyl group or an alkenyl group each having 9 to 35 carbon atoms. R3 represents an alkyl group or an alkenyl group each having 2 to 30 carbon atoms.) It is provided a ?-glucocerebrosidase activator which is easily available, and external skin preparations and a method of activating ?-glucocerebrosidase, in which improvement in formation of horny layer transmission barrier is expected by activating ?-glucocerebrosidase so that an improved effect in rough skin is also expected.Type: GrantFiled: June 27, 2002Date of Patent: February 27, 2007Assignee: Kao CorporationInventors: Rie Uematsu, Fumio Nakajima, Masahiro Yoshida, Kyoko Fukunaga, Mariko Hara, Shintaro Inoue, Shinichiro Nishimura
-
Patent number: 7179794Abstract: Disclosed are multibinding compounds which include macrolide antibiotics, aminoglycosides, lincosamides, oxazolidinones, streptoramins, tetracycline and/or other compounds which bind to bacterial ribosomal RNA and/or to one or more proteins involved in ribosomal protein synthesis in the bacterium, which are useful in treating bacterial infections. The compounds adversely affect protein expression and have an antibacterial effect. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is macrolide antibiotic, aminoglycoside, lincosamide, oxazolidinone, streptogramin, tetracycline or other compound which binds to bacterial ribosomal RNA and/or one or more proteins involved in ribosomal protein synthesis in the bacterium.Type: GrantFiled: December 27, 2002Date of Patent: February 20, 2007Assignee: Theravance, Inc.Inventors: John H. Griffin, John L. Pace
-
Patent number: 7157078Abstract: This invention relates to devices, kits, and methods for eliminating termite colonies. The kits, devices, and methods employ a termiticidal bait matrix containing a) a termiticide selected such that the termiticide causes death to about 50 to about 100% of termites within about 24 to about 84 days after the termites begin to ingest the termiticide or the bait matrix comprising the termiticide, b) a cellulose containing material, and c) water. The termiticidal bait matrix can be used in a bait station installed in the ground. The kits are suitable to be used by consumers in their homes.Type: GrantFiled: February 2, 2004Date of Patent: January 2, 2007Assignee: The University of Florida Research Foundation, Inc.Inventors: Philip Frederick Brode, III, Garry Steven Garren, Leo Timothy Laughlin, Randall Stryker Matthews, Dale Edwin Barker, Daniel James Kinne, Gary Eugene McKibben, Christopher Miles Miller, Timothy Robert Probst
-
Patent number: 7153826Abstract: Cyclic peptide antibiotics including the loloatins are effective in the treatment of rosacea, particularly when administered in conjunction with an antibiotic such as metronidazole that is effective against anaerobic bacteria.Type: GrantFiled: March 19, 2001Date of Patent: December 26, 2006Assignee: Seatek Marine Biotechnology, Inc.Inventor: Michael T. Kelly
-
Patent number: 7153877Abstract: A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.Type: GrantFiled: December 9, 2004Date of Patent: December 26, 2006Assignee: Interhealth Nutraceuticals IncorporatedInventors: Debasis Bagchi, Harry G. Preuss, Shil C. Kothari
-
Patent number: 7132402Abstract: This invention provides smooth muscle cell proliferation inhibitors of formula I having the structureType: GrantFiled: October 31, 2003Date of Patent: November 7, 2006Assignee: WyethInventors: Scott Christian Mayer, Robert E. McDevitt, Paul J. Dollings
-
Patent number: 7129219Abstract: This invention provides compounds containing a 2-deoxy-2-amino-?-D-glucopyranose (glucosamine) glycosidically linked to a cyclic aminoalkyl (aglycon) group. The invention further provides methods for inducing an immune response using the compounds of the present invention in the presence or absence of an antigen. In addition, methods for treating disease with the compounds of the present invention with or without an antigen are also provided in this invention.Type: GrantFiled: August 3, 2001Date of Patent: October 31, 2006Assignee: Corixa CorporationInventors: David A. Johnson, C. Gregory Sowell
-
Patent number: 7119110Abstract: A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.Type: GrantFiled: October 4, 2002Date of Patent: October 10, 2006Assignee: Interhealth Nutraceuticals IncorporatedInventors: Debasis Bagchi, Harry G. Preuss, Shil C. Kothari
-
Patent number: 7094431Abstract: This invention pertains to therapeutic antibacterial/antifungal-wound healing compositions comprising a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) zinc oxide; (b) calcium channel blocker, and (c) fat-soluble vitamins admixed with antibacterial and antifungal agents. The therapeutic antibacterial/antifungal-wound healing compositions may be utilized in a wide variety of pharmaceutical products and administered orally or topically.Type: GrantFiled: September 30, 2003Date of Patent: August 22, 2006Inventor: Mickey L. Peshoff
-
Patent number: 7060732Abstract: Two separate compositions, one containing an effective anti-acne treating amount of a first active ingredient and one containing a second active ingredient that is incompatible with the first active ingredient are packaged within and dispensed from a common dispenser. By packaging these two active ingredients in this manner, long shelflife and convenient dispensing and application are provided.Type: GrantFiled: April 12, 2002Date of Patent: June 13, 2006Assignee: Imaginative Research Associates, Inc.Inventors: Mohan Vishnupad, Naomi Vishnupad
-
Patent number: 7056702Abstract: The invention provides antibodies reactive with distinct lipocalin epitopes that are useful for detecting inflammation and bacterial infections in mammals.Type: GrantFiled: December 16, 2002Date of Patent: June 6, 2006Inventors: Julie M. Villanueva, Stephen Quirk
-
Patent number: 7029671Abstract: The invention relates to a method for activating human-derived antigen-presenting cells by in vitro cultivation with at least one of the glycoside compounds represented by formula (A) or salts thereof [preferred example: (2S,3S,4R)-1-(?-D-galactopyranosyloxy)-2-hexacosanoylamino-3,4-octadecanediol], and to human antigen-presenting cells activated by the method. The invention also relates to a method for treatment of cancer and infectious diseases including AIDS with the activated human antigen-presenting cells, and to a use of the activated human antigen-presenting cells in the preparation of medicines for treating such diseases. The invention can provide a satisfactory therapeutic effect on cancer and infectious diseases including AIDS without the need to pulse the human antigen-presenting cells with tumor antigens.Type: GrantFiled: November 27, 2000Date of Patent: April 18, 2006Assignee: Kirin Brewery Company, LimitedInventors: Yasuhiko Koezuka, Yasunori Yamaguchi, Kazuhiro Motoki
-
Patent number: 7026301Abstract: The present invention relates to the treatment of inflammatory skin conditions, including psoriasis, with a prodrug of 5-fluorouracil. The invention relates to methods for treatment of psoriasis with capecitabine, an oral prodrug of 5-fluorouracil.Type: GrantFiled: October 17, 2003Date of Patent: April 11, 2006Assignee: New York UniversityInventors: Timothy J. Cardozo, John C. Pui
-
Patent number: 6979675Abstract: The compound 2-deoxyglucose can be used to treat cancer and to improve patient outcome when administered at a therapeutically effective dose, and, optionally, co-administered with other anti-cancer drugs, or in combination with surgical resection or radiation therapy.Type: GrantFiled: January 9, 2004Date of Patent: December 27, 2005Assignee: Threshold Pharmaceuticals, Inc.Inventor: George Tidmarsh
-
Patent number: 6911434Abstract: Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ cyclic AGPs for selectively stimulating immune responses in animals and plants.Type: GrantFiled: February 4, 2002Date of Patent: June 28, 2005Assignee: Corixa CorporationInventors: Jory R. Baldridge, David A. Johnson, Christopher W. Cluff
-
Patent number: 6908903Abstract: Cluster clearing agents (CCAs) and the use thereof are discussed. CCAs are composed of a hepatic clearance directing moiety which directs the biodistribution of a CCA-containing construct to hepatic clearance; and a binding moiety which mediates binding of the CCA to a compound for which rapid hepatic clearance is desired.Type: GrantFiled: October 12, 2000Date of Patent: June 21, 2005Assignee: Aletheon Pharmaceuticals, Inc.Inventors: Louis J. Theodore, Donald B. Axworthy
-
Patent number: 6833362Abstract: A composition for accelerating the disposal of ethanol from bodily fluid. Certain additives can accelerate the metabolic oxidation of ethanol, and others in addition act as catalysts or “pseudo” enzymes for the oxidation. Additives include the oxidant Nicotinamide Adenine Dinucleotide and a variety of other additives such as transition metal ions and complexes thereof which favor the oxidation reaction. The compositions described can act as a sobriety inducer and/or as an effective palliative for the unpleasant effects of overuse of ethanol.Type: GrantFiled: June 7, 2001Date of Patent: December 21, 2004Inventors: Ward Beryl Bowen, Jr., Daniel Salman Daniel
-
Publication number: 20040242499Abstract: Galactosylceramide analogues represented by the following formula (1) or (2).Type: ApplicationFiled: December 24, 2003Publication date: December 2, 2004Inventors: Rie Uematsu, Fumio Nakajima, Masahiro Yoshida, Kyoko Fukunga, Mariko Hara, Shintaro Inoue, Shinichiro Nishimura
-
Publication number: 20040224904Abstract: Novel carbohydrate-based compounds with an attached ring system that have antimicrobial or cytostatic activity. The compounds are administered to humans and animals for the treatment or amelioration of bacterial, fungal, viral or protozoal infections or tumors.Type: ApplicationFiled: June 4, 2004Publication date: November 11, 2004Inventors: Benedikt Sas, Johan Van der Eycken, Johan Van hemel, Petra Blom, Jan Vandenkerckhove, Bart Ruttens
-
Publication number: 20040198668Abstract: The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.Type: ApplicationFiled: April 23, 2004Publication date: October 7, 2004Applicant: DUKE UNIVERSITYInventors: Kishore M. Gadde, K. Ranga R. Kaishnan
-
Patent number: 6800613Abstract: Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses in animals and plants.Type: GrantFiled: May 18, 2001Date of Patent: October 5, 2004Assignee: Corixa CorporationInventors: David H. Persing, Richard Thomas Crane, Gary T. Elliott, J. Terry Ulrich, Michael J. Lacy, David A. Johnson, Jory R. Baldridge, Rong Wang
-
Patent number: 6794370Abstract: A combination therapy for treating cancer including administering at least one camptothecin derivative in conjunction with another anticancer agent. The combination therapy is preferably used as a first-line therapy for treating metastatic colorectal cancer and preferably involves administration of a combination of CPT-11, 5-fluorouracil and folinic acid, according to specific infusional treatment schedules which show therapeutic synergy in the treatment of cancer.Type: GrantFiled: April 18, 2002Date of Patent: September 21, 2004Assignee: Aventis Pharma S.A.Inventor: Wolf R. Achterrath
-
Patent number: 6793921Abstract: The present invention provides specific antibodies obtained from eggs laid by hens which have been immunized against urease of Helicobacter pylori as an antigen, and specific antibodies obtained from eggs laid by hens which have been immunized against flagella of Helicobacter pylori as an antigen. These antibodies are useful for the prevention or treatment of gastritis, gastric ulcers and duodenal ulcers caused by infection of Helicobacter pylori. At least one organism selected from lactic acid bacteria, Enterococcuses, yeasts, and Baillus can be used along with the antibodies.Type: GrantFiled: June 24, 2002Date of Patent: September 21, 2004Assignees: Nisshin Pharma Inc., Ghen CorporationInventors: Yoshikatsu Kodama, Faustino C. Icatlo, Jr., Nobutake Kimura, Masato Ariga
-
Patent number: 6790937Abstract: The present invention relates to (a) variable regions of heavy and light chains of an antibody specific to a surface antigen in sporozoite of Eimeria spp.; (b) a recombinant scFV (single chain variable fragment) antibody prepared using the variable regions; (c) a method for preparing a recombinant scFv antibody; and (d) an expression vector for expressing a recombinant scFv antibody.Type: GrantFiled: February 26, 2002Date of Patent: September 14, 2004Assignee: Avicore Biotechnology Institute Inc.Inventors: Jin-Kyoo Kim, Jae-Yong Han, Ki-Duck Song, Sung-Won Kim, Won-Gi Min, Eun-Jung Son, Hyun Soon Lillehoj, Erik Peter Lillehoj